Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

A 22-year-old male experienced progress with 0.5 mg daily finasteride for hair loss but noticed recent shedding, which may be a synchronized shed. Users suggest continuing the current dose, considering increasing to 1 mg, or exploring additional treatments like GHK-cu, while noting that watery semen is a common side effect.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

A 22-year-old male uses dutasteride, a serum with 10% minoxidil and 0.5% finasteride, and microneedling for diffuse androgenetic alopecia. Progress pictures show changes from July 2025 to February 2026.

A 19-year-old male using 1 mg finasteride every two days for hair loss reports no side effects and believes maintaining his current hair condition is progress. Some users see no difference in hair regrowth, attributing changes to lighting.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

A 22-year-old male has been using finasteride for 4 months without major side effects but is concerned about hormone test results showing low SHBG and high estrogen. He plans to consult a doctor and is considering alternatives like minoxidil or topical finasteride to avoid health issues.

Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

A user shared their 16-month hair regrowth progress using finasteride, oral minoxidil, and micro-needling, noting significant improvement and minor side effects like stray ear hairs. Consistency in treatment was emphasized, with noticeable hair improvement within the first 6 months.

A user shared their hair regrowth progress using Dutasteride, topical Minoxidil, Spironolactone, and Estradiol Valerate injections as part of hormone replacement therapy for transitioning. They experienced significant hair improvement and personal satisfaction but caution against this approach for non-transitioning individuals due to irreversible changes.

GT20029 is anticipated to start phase III trials in Q3 2026, with potential public availability around 2029-2030.

GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.

A 20-year-old shared six months of hair regrowth progress using 1mg finasteride, 5% topical minoxidil, and recently started using a derma stamp. The user is pleased with the results and obtained finasteride through an online pharmacy.

A 24-year-old uses microneedling, tretinoin, topical and oral minoxidil, and oral finasteride for hair growth, noticing baby hair growth and initial side effects that resolved. Another user shares a similar regimen, excluding finasteride.

GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.

A 32-year-old shares 2-month progress using oral finasteride, topical minoxidil, and weekly derma stamping for hair loss, noting early improvements and no side effects. Encouragement is given for continued progress.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The user shared progress pictures after 8 months of using oral finasteride and topical minoxidil for hair loss, noting a plateau and considering adding dutasteride and oral minoxidil. They experienced a shedding phase but saw some regrowth, and also use a derma stamp and GHK-CU injections.

The conversation is about the anticipation of results for a hair loss treatment study, specifically for GT20029, with expectations for the results to be released in the first quarter of 2024. No specific treatments were discussed.

The user shared progress on hair regrowth after a third verteporfin procedure, using oral dutasteride, extended-release oral minoxidil, and occasional microneedling. The results were positively received by others.

The user has been using Minoxidil, Finasteride, and HRT for hair regrowth, but is not fully satisfied with the progress after 11 months. They are considering changing treatments, including possibly switching to Dutasteride and adjusting their HRT regimen.

User shared 16-month progress using finasteride 1 mg/day and minoxidil 5% solution once/day, noting significant regrowth, especially in temporal peaks. Users discussed shedding, side effects, and positive feedback from others.

A 23-year-old shared progress pictures after five months on Finasteride, starting with 0.25mg and increasing to 1mg, reporting no side effects and noticeable hair improvement. The user is satisfied with the results and plans to continue the treatment, while others in the conversation discuss dosage, side effects, and alternative treatments.

The user is using finasteride and minoxidil for hair loss but feels progress is slow and is considering switching to dutasteride after 12 months. They notice minor shedding but are unsure if the medication is stabilizing their hair loss.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

The user switched from finasteride to oral dutasteride and is assessing hair regrowth progress after 5 months, with some users noting visible improvement in density and regrowth. The user is advised to continue with dutasteride as it may take over two years for full effects.

A 22-year-old has been using finasteride and minoxidil for six months and started dutasteride one month ago for hair loss. They are discussing progress and seeking comparisons to their condition before starting treatment.